Patheon purchases Italian plant
Patheon Inc., a Canadian provider of pharmaceutical contract manufacturing services, has finalized its purchase of a 300,000-square-foot pharmaceutical plant near Milan, Italy. The facility, which was a subsidiary of the Switzerland-based Roche Group, manufactures sterile/injectable dosage forms and solid, semi-solid and powder forms. According to Patheon executives, the acquisition allows the company to offer a broader range of manufacturing and formulation development services to the global pharmaceutical industry.
Additionally, Patheon has signed a non-binding letter of intent to acquire Bristol-Myers Squibb Co.`s manufacturing plant in Buffalo, NY. The 300,000-square-foot facility produces semi-solid dosage forms for prescription and OTC markets. The transaction, which is subject to approval, includes long-term contracts with Bristol-Myers Squibb for certain products currently manufactured at the site. — TGW